Watch out, Keytruda. Ferring's bladder cancer gene therapy rival has new data—and they look competitive

6th December 2019 Uncategorised 0

On the heels of an FDA speedy review for Keytruda’s potential use in non-muscle invasive bladder cancer, its close rival, a gene therapy by Ferring Pharmaceuticals spinout FerGene, has posted competitive late-stage data. But Merck has at least one upper hand.

More: Watch out, Keytruda. Ferring's bladder cancer gene therapy rival has new data—and they look competitive
Source: fierce